Covid vaccination drive: Many hesitant to sign Covaxin consent form

Tamil Nadu administered a mere 99 Covaxin doses out of the target of 600 on the first day of the vaccination. On Sunday, the state-administered 90 more Covaxin doses till 2 pm.

New Delhi: At least three of the 11 states — Tamil Nadu, Telangana and Bihar — that administered Bharat Biotech’s Covaxin on Saturday have pointed out that the beneficiaries were reluctant to sign the consent forms, resulting in less than 50% strike rate on the first day of the public immunisation drive.

Rajasthan stood out as an exception, saying it faced no hesitancy issues. It administered 314 Covaxin doses out of a target of 600 and also reported no adverse event from the Bharat Biotech vaccine, whose approval has sparked concerns.



“Our healthcare workers were reluctant in taking Covaxin. The biggest problem is the consent form they need to sign. On the first day we administered less than 200 Covaxin doses. We have opened Covaxin vaccination centres at super speciality and big government hospitals. We hope to create more awareness,” Telangana health minister Eatala Rajender said.

Tamil Nadu too red-flagged the issue at a coordination meeting convened by union health minister Harsh Vardhan on Saturday.

ETD-1-18012021

‘Dispelling Doubts’
ADVERTISEMENT
State health secretary J Radhakrishnan is believed to have said at the meeting that healthcare workers were reluctant to sign consent forms, but the state government was expecting to tide over the issue by spreading more awareness.

Tamil Nadu administered a mere 99 Covaxin doses out of the target of 600 on the first day of the vaccination. On Sunday, the state administered 90 more Covaxin doses till 2 pm.

Each of the 11 states, which agreed to administer Covaxin, have dedicated six vaccination centres for the purpose. These centres were restricted to the government hospitals. None of these states could achieve the target.

Bihar, which saw one of its Covaxin vaccination centres at Patna Medical College meet the full target of 100 doses, came close to the halfway mark. “We administered nearly 300 doses. AIIMS Patna director PK Singh took Covaxin shot to send a message that it is safe. We hope that this would encourage other health workers and dispel all doubts.”

ADVERTISEMENT
Rajasthan, which performed well on this score, said translating the consent form to Hindi helped. “We had received the consent form and we translated it to Hindi so that the healthcare workers could understand what they were signing. On the first day, we have achieved 314 vaccinations at Covaxin centres. We did not face any reluctance on forms but hope to improve on numbers this week,” Rajasthan National Health Mission director Naresh Thakral told ET.

Rajasthan also did not report a single case of adverse event following immunisation at the six Covaxin centres, which are in Jaipur.

ADVERTISEMENT
Vaccine hesitancy comes at a time when severe adverse events following immunisation (AEFI) have been reported recently. Twenty-nine elderly people died in Norway following administration of Pfizer vaccine on Saturday. Australia’s scientific community has raised doubts over the efficacy of Oxford-AstraZeneca vaccine.

India's Covid-19 vaccination drive starts successfully even as doubts remain over Covaxin
1/5

According to a report by AFP, India's Covid-19 vaccination drive had a successful start with more than 2,24,000 people receiving their first jabs and just three people hospitalised for experiencing side effects, the Health ministry said Sunday, as reports emerged about concerns over a homegrown vaccine.

According to a report by AFP, India's Covid-19 vaccination drive had a successful start with more than 2,24,000 people receiving their first jabs and just three people hospitalised for experiencing s..
Read More

Authorities have given emergency-use approval for two jabs -- "Covishield", a version of the Oxford-AstraZeneca vaccine, and the Indian-made "Covaxin", which has yet to complete its Phase 3 trials. The government plans to immunise some 300 million people out of its population of 1.3 billion by July.

Authorities have given emergency-use approval for two jabs -- "Covishield", a version of the Oxford-AstraZeneca vaccine, and the Indian-made "Covaxin", which has yet to complete its Phase 3 trials. T..
Read More

Frontline workers such as hospital staff, people over 50 and those deemed to be at high risk due to pre-existing medical conditions are on the shortlist to receive the vaccines. "We have got encouraging and satisfactory feedback results on the first day," Health Minister Harsh Vardhan told his state counterparts on Saturday. "This vaccine will indeed be a 'Sanjeevani' (life saver)" in the fight against the virus, he added.

Frontline workers such as hospital staff, people over 50 and those deemed to be at high risk due to pre-existing medical conditions are on the shortlist to receive the vaccines. "We have got encourag..
Read More

The health ministry said Sunday that 447 people reported experiencing side effects -- mostly fever, headache and nausea -- after being given their shot, with three people admitted to hospital. Two have already been discharged, the ministry added.

The health ministry said Sunday that 447 people reported experiencing side effects -- mostly fever, headache and nausea -- after being given their shot, with three people admitted to hospital. Two ha..
Read More

The updated vaccination figures came as a doctors' representative body at the Dr Ram Manohar Lohia Hospital in New Delhi wrote a letter asking for the Covishield vaccine to be supplied instead of Covaxin. "The residents are a bit apprehensive about the lack of complete trial in case of Covaxin and might not participate in huge numbers thus defeating the purpose of vaccination," said the letter addressing the hospital's medical superintendent, seen by AFP.

The updated vaccination figures came as a doctors' representative body at the Dr Ram Manohar Lohia Hospital in New Delhi wrote a letter asking for the Covishield vaccine to be supplied instead of Cov..
Read More


READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Text Size:AAA
Success
This article has been saved

*

+